Literature DB >> 27357429

Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Akira Kurozumi1,2, Yusuke Goto1,2, Atsushi Okato1,2, Tomohiko Ichikawa2, Naohiko Seki1.   

Abstract

Bladder cancer (BC) and renal cell carcinoma (RCC) are frequently diagnosed urinary tract cancers. Recently developed molecular-targeted therapies for RCC have shown remarkable therapeutic efficacy; however, no targeted therapeutics are currently approved for the treatment of BC, and few effective treatment options exist. Current studies have shown that small noncoding RNA molecules have major roles in cancer cells. MicroRNAs (miRNAs) are endogenous small noncoding RNA molecules that regulate protein-/nonprotein-coding RNAs in human cells. A large body of evidence suggests that aberrantly expressed miRNAs are deeply involved in the pathogenesis of human cancers. In this paper, we review recently published miRNA expression signatures of BC and RCC. We focus on downregulated or upregulated miRNAs in multiple signatures and discuss putative target genes of miRNAs. Comparisons of RCC and BC expression signatures revealed that the two types of cancer showed opposite expression patterns for miR-200 family miRNAs (i.e., miR-141/200c and miR-200a/200b/429). We discuss in silico analysis of genes targeted by miR-200 family miRNAs and the molecular mechanisms underlying BC and RCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27357429     DOI: 10.1038/jhg.2016.84

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  87 in total

1.  KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells.

Authors:  Baotong Zhang; Zhiqian Zhang; Siyuan Xia; Changsheng Xing; Xinpei Ci; Xin Li; Ranran Zhao; Sha Tian; Gui Ma; Zhengmao Zhu; Liya Fu; Jin-Tang Dong
Journal:  Mol Cell Biol       Date:  2013-10-14       Impact factor: 4.272

Review 2.  Functional significance of aberrantly expressed microRNAs in prostate cancer.

Authors:  Yusuke Goto; Akira Kurozumi; Hideki Enokida; Tomohiko Ichikawa; Naohiko Seki
Journal:  Int J Urol       Date:  2015-01-20       Impact factor: 3.369

3.  The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.

Authors:  Satoko Kojima; Hideki Enokida; Hirofumi Yoshino; Toshihiko Itesako; Takeshi Chiyomaru; Takashi Kinoshita; Miki Fuse; Rika Nishikawa; Yusuke Goto; Yukio Naya; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

4.  Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.

Authors:  Lars Dyrskjøt; Marie S Ostenfeld; Jesper B Bramsen; Asli N Silahtaroglu; Philippe Lamy; Ramshanker Ramanathan; Niels Fristrup; Jens L Jensen; Claus L Andersen; Karsten Zieger; Sakari Kauppinen; Benedicte P Ulhøi; Jørgen Kjems; Michael Borre; Torben F Orntoft
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

5.  Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma.

Authors:  Hirofumi Yoshino; Hideki Enokida; Toshihiko Itesako; Shuichi Tatarano; Takashi Kinoshita; Miki Fuse; Satoko Kojima; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-05-02       Impact factor: 3.172

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells.

Authors:  Manjari Dimri; Mingu Kang; Goberdhan P Dimri
Journal:  Oncotarget       Date:  2016-06-14

8.  miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2.

Authors:  Yu Gao; Xin Ma; Yuanxin Yao; Hongzhao Li; Yang Fan; Yu Zhang; Chaofei Zhao; Lei Wang; Minghui Ma; Zhengwei Lei; Xu Zhang
Journal:  Oncotarget       Date:  2016-04-12

9.  MicroRNA-200 family modulation in distinct breast cancer phenotypes.

Authors:  María Ángeles Castilla; Juan Díaz-Martín; David Sarrió; Laura Romero-Pérez; María Ángeles López-García; Begoña Vieites; Michele Biscuola; Susana Ramiro-Fuentes; Clare M Isacke; José Palacios
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  MicroRNA-224 sustains Wnt/β-catenin signaling and promotes aggressive phenotype of colorectal cancer.

Authors:  Tingting Li; Qiuhua Lai; Shuyang Wang; Juanjuan Cai; Zhiyuan Xiao; Danling Deng; Liuqing He; Hongli Jiao; Yaping Ye; Li Liang; Yanqing Ding; Wenting Liao
Journal:  J Exp Clin Cancer Res       Date:  2016-01-29
View more
  23 in total

1.  MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma.

Authors:  Xinwen Ke; Xing Zeng; Xian Wei; Yuanqing Shen; Jiahua Gan; Huake Tang; Zhiquan Hu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma.

Authors:  Zhigang Tong; Xianfeng Meng; Jinsong Wang; Lixin Wang
Journal:  Exp Ther Med       Date:  2017-09-21       Impact factor: 2.447

Review 3.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

Review 4.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

5.  Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.

Authors:  Yasutaka Yamada; Rika Nishikawa; Mayuko Kato; Atsushi Okato; Takayuki Arai; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2017-12-01       Impact factor: 3.172

Review 6.  Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

Authors:  Zhongwei Zhao; Carsten Stephan; Sabine Weickmann; Monika Jung; Glen Kristiansen; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

7.  Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.

Authors:  Takayuki Arai; Atsushi Okato; Satoko Kojima; Tetsuya Idichi; Keiichi Koshizuka; Akira Kurozumi; Mayuko Kato; Kazuto Yamazaki; Yasuo Ishida; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  Cancer Sci       Date:  2017-08-19       Impact factor: 6.716

8.  MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples.

Authors:  Michael S Kent; Allison Zwingenberger; Jodi L Westropp; Laura E Barrett; Blythe P Durbin-Johnson; Paramita Ghosh; Ruth L Vinall
Journal:  BMC Vet Res       Date:  2017-11-15       Impact factor: 2.741

9.  LncRNA HAND2-AS1 exerts anti-oncogenic effects on bladder cancer via restoration of RARB as a sponge of microRNA-146.

Authors:  Liping Shan; Wei Liu; Yunhong Zhan
Journal:  Cancer Cell Int       Date:  2021-07-08       Impact factor: 5.722

10.  The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster.

Authors:  Keiichi Yonemori; Naohiko Seki; Tetsuya Idichi; Hiroshi Kurahara; Yusaku Osako; Keiichi Koshizuka; Takayuki Arai; Atsushi Okato; Yoshiaki Kita; Takaaki Arigami; Yuko Mataki; Yuko Kijima; Kosei Maemura; Shoji Natsugoe
Journal:  Oncotarget       Date:  2017-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.